An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Generation Bio Co. (GBIO) CEO to participate in fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The event will be webcasted live and available for replay for 30 days.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
When will Geoff McDonough, M.D., participate in the fireside chat?
Geoff McDonough, M.D., will participate in the fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. ET.
Where can the live webcast of the presentation be viewed?
The live webcast of the presentation will be available on the investor section of Generation Bio Co.'s website at investors.generationbio.com.
How long will the replay of the event be available?
The replay of the event will be available on Generation Bio Co.'s website for 30 days following the fireside chat.
generation bio is creating a revolutionary new class of genetic medicines that deliver durable, high levels of gene expression and have drug-like properties, including ability to titrate to effect and re-dose. our unique genewave technology allows us to overcome the limitations of other approaches by delivering larger genes, including more sophisticated regulatory elements, and avoiding the immunogenicity which limits both the number of patients who can be treated and the ability to re-dose them over time. we are a community of creative problem-solvers and independent thinkers. we are guided by strong personal integrity, humility, and the collaborative, learning mindset required to create solutions for patients and their families. to learn more about our efforts to usher in a new generation in medicine, please visit www.generationbio.com or our twitter feed, @lifetimegenetx.